Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bluejay Diagnostics (BJDX) Liabilities and Shareholders Equity (2020 - 2026)

Bluejay Diagnostics' Liabilities and Shareholders Equity history spans 3 years, with the latest figure at $4.9 million for Q4 2023.

  • On a quarterly basis, Liabilities and Shareholders Equity fell 63.99% to $4.9 million in Q4 2023 year-over-year; TTM through Dec 2023 was $32.5 million, a 51.79% decrease, with the full-year FY2023 number at $4.9 million, down 63.99% from a year prior.
  • Liabilities and Shareholders Equity hit $4.9 million in Q4 2023 for Bluejay Diagnostics, down from $8.2 million in the prior quarter.
  • Over the last five years, Liabilities and Shareholders Equity for BJDX hit a ceiling of $21.0 million in Q4 2021 and a floor of $4.9 million in Q4 2023.
  • Historically, Liabilities and Shareholders Equity has averaged $13.4 million across 3 years, with a median of $13.5 million in 2022.
  • Biggest five-year swings in Liabilities and Shareholders Equity: tumbled 35.67% in 2022 and later plummeted 63.99% in 2023.
  • Tracing BJDX's Liabilities and Shareholders Equity over 3 years: stood at $21.0 million in 2021, then crashed by 35.67% to $13.5 million in 2022, then plummeted by 63.99% to $4.9 million in 2023.
  • Business Quant data shows Liabilities and Shareholders Equity for BJDX at $4.9 million in Q4 2023, $8.2 million in Q3 2023, and $8.5 million in Q2 2023.